Palisade Bio (PALI) News Today

Palisade Bio, Inc. (NASDAQ: PALI) has moved lower despite several favorable development and analyst updates. The decline may reflect profit-taking, volatility and uncertainty around the company’s early-stage clinical programs rather than a newly reported negative fundamental result.

• Positive Sentiment: Health Canada cleared the company’s clinical trial application for the global Phase 2 ASCENTRA-UC study of PALI-2108 in ulcerative colitis. The clearance allows the program to advance toward broader clinical testing and is a meaningful regulatory milestone. Palisade Bio Receives Health Canada CTA Clearance
• Positive Sentiment: Palisade Bio also received FDA clearance for the PALI-2108 investigational new drug application in Crohn’s disease, supporting development of the company’s PDE4 inhibitor platform in another inflammatory bowel disease indication. Palisade Bio Gets FDA Clearance for PALI-2108
• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating, while other analyst coverage characterized PALI favorably. These endorsements may support investor sentiment, although they do not guarantee clinical or commercial success. HC Wainwright Reaffirms Buy Rating
• Neutral Sentiment: A reported September short-interest figure of zero shares implies no measurable short positioning, but the item also describes a “large increase,” indicating the data may be inconsistent and should be interpreted cautiously.
• Negative Sentiment: One report said Palisade backed away from an FSCD-related opportunity. Without additional details, the development could raise questions about strategic priorities, though its direct financial impact is unclear. Palisade Backs Away from FSCD